

# JTTS CLINICAL PRACTICE GUIDELINES FOR THE PREVENTION OF DEEP VEIN THROMBOSIS

## 1. REFERENCES.

- a. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines, **Chest**; 126:3(Supplement), September 2004
- b. Practice Management Guidelines for the Management of Venous Thromboembolism in Trauma Patients, Eastern Association for the Surgery of Trauma, [www.east.org](http://www.east.org), May 8, 2006
- c. Scurr JH; Machin SJ; Bailey-King S; Mackie IJ; McDonald S; Smith PD, "Frequency and Prevention of Symptom-less Deep Venous Thrombosis in Long Haul Flights: A Randomized Trial, **Lancet** 357:1485-9, 2001
- d. Knudson MM, Morabito D, Paiement GD, et al: Use of low molecular weight heparin in preventing thromboembolism in trauma patients. **J Trauma** 41:446-59, 1996
- e. Knudson MM, Lewis FR, Clinton A, et al: Prevention of venous thromboembolism in trauma patients. **J Trauma** 37:480-7, 1994
- f. Geerts WH, Code KJ, Jay RM, et al: A prospective study of venous thromboembolism after major trauma. **N Engl J Med** 331:1601-6, 1994
- g. Geerts WH, Jay RM, Code KJ, et al: A comparison of low-dose heparin with low-molecular weight heparin as prophylaxis against venous thromboembolism after major trauma. **N Engl J Med** 335:701-7, 1996

2. **PURPOSE.** The purpose of this clinical practice guideline is to establish guidance for antithrombotic therapy for the prevention of deep vein thrombosis. These recommendations are guidelines only and are not a substitute for clinical judgment.

3. **APPLICABILITY.** This memorandum applies to personnel assigned or attached to OIF intra-theatre medical facilities who are involved in the management of patients.

## 4. BACKGROUND.

- a. The Seventh American College of Chest Physicians Conference recommended that, "every hospital should develop a written policy or other formal strategy for preventing thromboembolic complications, especially for high-risk patients."
- b. Proximal deep vein thrombosis (DVT) continues to be a frequent complication in hospitalized patients. Pulmonary embolism, a very serious potential outcome from DVT, has been seen in over 20% of patients hospitalized with DVTs in national reviews and is a major cause of morbidity and mortality in these patients.
- c. There is an increasing recognition of DVT in individuals who complete an extended period of travel on an airplane. One study noted a 10% prevalence of asymptomatic DVT in individuals undergoing flights of 8 hours or more. Landstuhl Regional Medical Center is uniquely positioned to receive patients who have undergone extensive periods of travel prior to admission.
- d. Different societies and working groups have published varying recommendations for DVT prophylaxis. Where these recommendations disagree, the clinical guidelines recommended here represent the guideline with a higher level of scientific evidence supporting the recommendation or a more conservative recommendation.
- e. Because of the short aero medical evacuation times achievable in our system today, it may be possible that certain patients will still be receiving blood product therapy to correct coagulopathy when they enter the chain. It is inherent on providers at each step in the aero medical evacuation chain to evaluate patients for DVT prophylaxis and make adjustments in therapy as clinically appropriate. It is recommended to begin DVT prophylaxis therapy as soon as coagulopathy is corrected in patients not otherwise at increased risk of bleeding.

GUIDELINE ONLY—NOT A SUBSTITUTE FOR CLINICAL JUDGEMENT

Update: July 2006

JTTS CLINICAL PRACTICE GUIDELINES FOR  
THE PREVENTION OF DEEP VENOUS THROMBOSIS

**5. RESPONSIBILITIES.**

**a. All Health Care Providers will:**

- (1) Become familiar with the guidelines for the prevention of DVT (see Appendix A).
- (2) Appropriately manage patients who may be at risk of DVT.
- (3) Provide feedback on these guidelines and suggestions for changes to the CPG to the JTTS.

**b. The Chief, Surg/Med at each Level III facility will:**

- (1) Review all thromboembolic events in the Level III facility to assess ways to reduce the risk to the patient.
- (2) Coordinate with the Theatre Trauma Coordinator on the appropriateness of the guidelines being used and provide input for updates on an as needed basis.

**c. The Theater Trauma Director will:**

- (1) Be the subject matter expert on the guidelines to be used in the entire OIF/OEF theatre for antithrombotic therapy for the prevention of DVT.
- (2) Update the guidelines on an as-needed basis.

**6. PROPONENT.** The proponent for these guidelines is the CentCom JTTS.

**APPROVED:**

Donald H Jenkins  
Col USAF MC  
Trauma Medical Director  
US CENTCOM JTTS

# JTTS CLINICAL PRACTICE GUIDELINES FOR THE PREVENTION OF DEEP VENOUS THROMBOSIS

## **Risk Group**

### **TRAUMA SURGERY**

Emergency trauma surgical procedures in patients with prohibitive risk of bleeding, or ongoing coagulopathy

Emergency trauma surgical procedures in all patients, except patients with prohibitive risk of bleeding (once coagulopathy not present)

Isolated major orthopedic surgery of extremities, spine, and pelvis

### **IVC FILTER PLACEMENT**

Patients with:

1. Recurrent PE despite full anticoagulation
2. Proximal DVT and contraindications to full anticoagulation
3. Proximal DVT and major bleeding while on full anticoagulation
4. Progression of iliofemoral clot despite anticoagulation

Patients with established DVT or PE and:

1. Large free-floating thrombus in the iliac vein or IVC
2. Following massive PE in which recurrent emboli may prove fatal
3. During/after surgical embolectomy

Very high risk trauma patients: who cannot receive anticoagulation because of increased bleeding risk and:

1. Severe closed head injury (GCS <8)
2. Incomplete spinal cord injury with paraplegia or quadriplegia
3. Complex pelvic fractures with associated long-bone fractures
4. Multiple long-bone fractures

### **ROLE OF DUPLEX SCREENING**

Asymptomatic patients

Symptomatic patients

## **Prophylactic Measures**

SCD (sequential compression device) until able to be anticoagulated (ideally start Lovenox within 12 hours of cessation of coagulopathy); see IVC filter section below

Lovenox 30 mg BID  
Strongly consider adding SCD

SCD device + Lovenox 30 mg BID;  
See IVC filter section below  
Continue tx for 7-10 days postop

Level I evidence for placement of IVC filter

Level II evidence for "extended" indications for prophylactic IVC filter for patients with established DVT or PE

Level III evidence for consideration of placement of prophylactic placement of IVC filter. Impact of retrievable filters is unclear in this patient population.

Serial duplex ultrasound imaging of high-risk patients may be cost effective and decrease the incidence of PE (Level III). Screening of asymptomatic patients is burdened by low sensitivity compared to venography

Duplex ultrasound may be used without confirmatory venography (Level I)

**GUIDELINE ONLY—NOT A SUBSTITUTE FOR CLINICAL JUDGEMENT**

Update: July 2006

JTTS CLINICAL PRACTICE GUIDELINES FOR  
THE PREVENTION OF DEEP VENOUS THROMBOSIS

**GENERAL SURGERY**

Low Risk (minor procedure in patients < 40 years, no factors)

Early mobilization

Moderate Risk (minor procedure with additional risk factors for thrombosis; non-major surgery in patients 40-60 years, with no additional risk factors; major surgery in patients <40 years with no additional risk factors)

Unfractionated Heparin 5000 U BID or Lovenox 40 mg QD

Higher Risk (non-major surgery in patients >60 years or have additional risk factors; major surgery in patients >40 years or have additional risk factors)

Unfractionated Heparin 5000 U TID or Lovenox 30 mg BID

High Risk (patients with multiple risk factors)

Unfractionated Heparin 5000 U TID or Lovenox 30 mg BID **plus** GCS (graduated compression stocking) or SCD

Moderate Risk or higher patients with high risk of bleeding

GCS or SCD

**VASCULAR SURGERY**

Patients without additional thromboembolic risk factors

No need for thromboprophylaxis

Patients with additional thromboembolic risk factors

Unfractionated Heparin 5000 U BID or Lovenox 40 mg QD

**UROLOGIC SURGERY**

Low risk urologic procedures

Early ambulation

Major, open urologic procedures

Unfractionated Heparin 5000 U BID or TID

Patients actively bleeding or at risk for bleeding

GCS or SCD

Patients with multiple risk factors

GCS or SCD and Unfractionated Heparin 5000 U BID or TID or Lovenox 40 mg QD

**NEUROSURGERY**

Intracranial neurosurgical procedures

SCD with or without GCS

High-risk neurosurgery patients

SCD and/or GCS

GUIDELINE ONLY—NOT A SUBSTITUTE FOR CLINICAL JUDGEMENT

Update: July 2006